KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) EBT Margin (2016 - 2025)

Regeneron Pharmaceuticals has reported EBT Margin over the past 17 years, most recently at 26.87% for Q4 2025.

  • Quarterly results put EBT Margin at 26.87% for Q4 2025, up 158.0% from a year ago — trailing twelve months through Dec 2025 was 36.47% (up 281.0% YoY), and the annual figure for FY2025 was 36.47%, up 281.0%.
  • EBT Margin for Q4 2025 was 26.87% at Regeneron Pharmaceuticals, down from 46.97% in the prior quarter.
  • Over the last five years, EBT Margin for REGN hit a ceiling of 2122.2% in Q1 2022 and a floor of 22.28% in Q1 2024.
  • Median EBT Margin over the past 5 years was 40.72% (2024), compared with a mean of 345.66%.
  • Biggest five-year swings in EBT Margin: surged 207265bps in 2022 and later tumbled -209507bps in 2023.
  • Regeneron Pharmaceuticals' EBT Margin stood at 2086.17% in 2021, then dropped by -2bps to 2038.0% in 2022, then plummeted by -98bps to 33.42% in 2023, then decreased by -24bps to 25.29% in 2024, then grew by 6bps to 26.87% in 2025.
  • The last three reported values for EBT Margin were 26.87% (Q4 2025), 46.97% (Q3 2025), and 41.32% (Q2 2025) per Business Quant data.